Chime Biologics, a China-based CDMO, has secured a total commitment of $190 million investment from institutional investors. This round of financing was led by VMS Group, followed by Fidelity International and Panacea Venture. Previously Chime Biologics had just completed its Series A round financing of $125 million in early 2020.   Chime Biologics says it has built the world’s first GE KuBio modular biomanufacturing facility in Wuhan Bio-Lake Biotech Industry Development Zone of China (Ch...